Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference

Core Insights - Karyopharm Therapeutics Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, at 10:30 a.m. ET in New York, NY [1] - A live webcast of the event will be available on the company's investor website and can be replayed after the event [2] Company Overview - Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on developing novel cancer therapies, particularly oral compounds that target nuclear export dysregulation, a key mechanism in cancer development [3] - The company's lead product, XPOVIO® (selinexor), is an oral exportin 1 (XPO1) inhibitor approved in the U.S. for three oncology indications and has received regulatory approvals in 50 territories, including the EU, UK (as NEXPOVIO), and China [3] - Karyopharm's pipeline targets multiple high unmet need cancers, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL) [3]